HerAnova Lifesciences

07/28/2026

New real-world clinical data presented at the Midwest Reproductive Symposium international 2026 Conference, highlighted the potential of HerResolve™ to help address the longstanding challenges of delayed endometriosis diagnosis.

Out of 197 women evaluated in clinical practice, HerResolve™ demonstrated:

· 53%, were detected as positive for endometriosis
· Use across multiple clinical sites and providers, reflecting broad early adoption
· Consistent algorithm performance across a diverse patient population with symptoms including infertility, pelvic pain and abnormal uterine bleeding

These real-world findings support the feasibility of HerResolve™ across multiple providers and clinical settings and reinforce the need for innovative approaches that may help shorten the journey to diagnosis.

We're excited to share these findings with the reproductive medicine community!

Check out our press release to learn more: https://heranova.com/2026/07/28/07-28-2026/

07/24/2026

Endometriosis is more common than many realize, yet its impact on pregnancy is still not fully understood, affecting both natural conception and assisted reproductive outcomes.

Research published in the Journal of Personalized Medicine highlights that women with endometriosis face elevated risks for obstetric complications, including preterm birth and small-for-gestational-age infants.

Even when a patient is moving forward with IVF, knowing whether endometriosis is present beforehand can help guide a more individualized approach to care, monitoring, and pregnancy planning.

At HerAnova, we are advancing non-invasive diagnostics like HerResolve™, our blood test aimed at helping identify endometriosis earlier in the fertility journey.

Read more about the impact of endometriosis on pregnancy here: https://pmc.ncbi.nlm.nih.gov/articles/PMC10820275/

Despite the increased frequency of endometriosis, it remains one of the most enigmatic disorders regarding its effects on pregnancy. Endometriosis adversely affects both natural and assisted conception. Impaired folliculogenesis, which causes ...

07/21/2026

We're looking forward to joining the reproductive medicine community at the Midwest Reproductive Symposium international (MRSi) 2026 Conference, taking place July 26-29 in Chicago.

Our VP of Marketing, Cory Dunn, will present a poster highlighting new real-world clinical data on HerResolve™, our multi-omic, non-invasive blood-based molecular test designed to detect endometriosis in symptomatic women.

If you're attending MRSi, stop by our poster to learn more about the data and connect with our team. We look forward to seeing you in Chicago!

07/15/2026

Across women's health, innovation is most meaningful when it helps connect diagnosis, treatment, and care planning.

HerAnova is focused on developing integrated care solutions for women's health, specifically in endometriosis and female fertility.

Through internally developed and externally partnered diagnostics, drugs, and devices, we are working to help address critical unmet needs and support more personalized care for women and their physicians.

Learn more: https://heranova.com/about-us/

07/10/2026

Thank you Kate and Bryan for helping bring awareness to this systemic disease that affects many women yet often takes years to diagnose. We’re hoping to change that narrative for women everywhere with HerResolve. ❤️

07/10/2026

We're proud to see our Chief Medical Officer, Dr. Farideh Bischoff, featured in Healio discussing the clinical validation of HerResolve™, our first-of-its-kind multiomic blood test for endometriosis.

The data presented at ENDO 2026 demonstrated that HerResolve identified 61.5% of endometriosis cases missed by transvaginal ultrasound, MRI, or both, underscoring its potential to provide earlier answers for women seeking a diagnosis.

As Dr. Bischoff shared, "One of the greatest challenges with endometriosis is timely diagnosis." By providing clinicians with a noninvasive tool to complement existing diagnostic pathways, HerResolve has the potential to help women get answers sooner and support more informed treatment decisions.

Read the full Healio feature: https://www.healio.com/news/womens-health-ob-gyn/20260707/first-of-its-kind-blood-test-accurately-identifies-endometriosis

CHICAGO — A noninvasive blood-based test identified cases of endometriosis that were missed by imaging, data at the Endocrine Society annual meeting show.“One of the greatest challenges with endometriosis is timely diagnosis,” Farideh Bischoff, PhD, chief medical officer of HerAnov...

07/09/2026

HerAnova's Chief Medical Officer, Dr. Farideh Bischoff, and co-founder and chairwoman, Penny Wan, joined Dr. Susan Fox on the Health Youniversity podcast for a thoughtful conversation on endometriosis, fertility, and the need for earlier, less invasive ways to help women get answers.

In the episode, they discuss why menstrual pain should not be dismissed as "normal," how endometriosis can impact reproductive health, and HerAnova's work to advance HerResolve™, a blood-based test designed to support the diagnosis of endometriosis.

Thank you to Dr. Fox for giving HerAnova the opportunity to help raise awareness around endometriosis and the importance of supporting women and healthcare professionals in getting the answer they need to act.

Watch the full episode, "It's Not You; It's Endo! with HerAnova," here: https://www.youtube.com/watch?v=9Rg3GgQwXc4

💯 *Schedule Your Fertile Health Assessment.* https://healthyouniver...

07/02/2026

HerAnova was featured by GenomeWeb as the conversation around earlier, less invasive approaches to endometriosis diagnosis continues to grow.

As highlighted in the article, HerResolve™ combines multiple biomarkers and machine learning to help identify endometriosis in symptomatic women through a blood-based approach. The coverage also discussed our clinical validation data published in the Journal of Minimally Invasive Gynecology.

The article further highlights HerAnova’s ongoing efforts as we work to expand access to innovative diagnostic solutions across women’s healthcare in the United States.

We remain focused on helping women access answers sooner and supporting clinicians with additional diagnostic insights.

Thank you to Genome Web and Kelsy Ketchum for covering the progress being made in endometriosis diagnostics and the continued innovation in women’s health.

Read the full article here: https://www.genomeweb.com/reproductive-health/recent-data-heranova-lifesciences-makes-case-rule-endometriosis-test

The firm currently offers its HerResolve multiomic test for endometriosis that looks at seven biomarkers, including microRNAs and proteins.

06/25/2026

This new documentary "End of the Cycle" from The Endometriosis Collective and Sammy Jaye brings together Amy Schumer, Julianne Hough, Brittany Brown, Janel Parrish, and Fọláké Olówòfóyèkù to tell a story that is long overdue, including newly uncovered details about Marilyn Monroe's own endometriosis journey, connecting her experience to more than 265 million women living with this disease today.

Films like this matter because they move the conversation out of silence and into the mainstream, where research, funding, and real change can follow.

We encourage everyone to watch, share, and help carry this conversation forward.

Thank you to The Endometriosis Collective, the filmmakers, and everyone who courageously shared their story.

Stream "End of the Cycle" here: https://lnkd.in/eTcBK9jj

06/22/2026

ICYMI, our Chairwoman and Co-Founder Penny Wan participated in the Women in Finance Breakfast at the 2026 Sohn Hong Kong Investment Conference hosted by the Karen Leung Foundation - 梁愷昍婦癌基金會, joining investors, innovators, and healthcare leaders for an important discussion on the future of women's health.

One theme emerged clearly throughout the conversation: women's health is one of the largest untapped opportunities in healthcare innovation, with significant potential to improve outcomes for millions of women while creating meaningful value across the healthcare ecosystem.

Advances in precision medicine, artificial intelligence, and multiomics are transforming our ability to understand complex conditions that have historically been underdiagnosed and underserved. By combining biological data with advanced analytics, the next generation of diagnostics and therapeutics has the potential to deliver earlier answers, more personalized care, and better outcomes for patients.

We are encouraged by the growing momentum behind women's health and excited to be part of building the future of women's health!